skip to the content

NCCTG N9831 trial

 

A US, Phase III, randomised, multicentre, open-label trial of 1 year of adjuvant Herceptin given either concurrently with, or following, paclitaxel therapy compared with chemotherapy alone in HER2-positive EBC.